Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease

Among 1498 patients with coronary artery disease and type 2 diabetes, 17.6% received an SGLT2 inhibitor and 5.5% received a GLP-1 receptor agonist.

• The prescription of SGLT2 inhibitors increased by 38.7% and GLP-1 receptor agonists by 8% during the observation period.
• Lowering the GFR cut-off to 30 ml/min/1.73 m² could allow an additional 26.6% of patients to qualify for SGLT2 inhibitor therapy.
• SGLT2 inhibitor therapy is associated with a reduced risk of cardiovascular mortality, with an adjusted hazard ratio of 0.18.
• GLP-1 receptor agonist therapy showed a trend toward reduced cardiovascular mortality risk.
• There is infrequent prescription of SGLT2 inhibitors and GLP-1 receptor agonists despite their potential cardiovascular benefits.

AI simplified